Robin Sherrington's most recent trade in Xenon Pharmaceuticals Inc was a trade of 65,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 11, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 11 Mar 2024 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 7,407 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 7,407 | 16,824 (0%) | 0% | 9.9 | 72,959 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 6,118 | 8,398 (0%) | 0% | 46.3 | 283,263 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 1,289 | 15,535 (0%) | 0% | 46.0 | 59,242 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 1,234 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 1,234 | 9,632 (0%) | 0% | 9.9 | 12,155 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 1,019 | 14,516 (0%) | 0% | 46.2 | 47,027 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 07 Mar 2024 | 215 | 9,417 (0%) | 0% | 46.0 | 9,881 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 29 Dec 2023 | 8,398 | 8,398 (0%) | 0% | 0 | Common Shares | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 10 Mar 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 50,000 | 66,796 (0%) | 0% | 4.8 | 237,500 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 35,103 | 25,572 (0%) | 0% | 38.0 | 1,334,967 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 21,352 | 16,796 (0%) | 0% | 38.6 | 823,547 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 17,488 | 0 | - | - | Stock Options (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 17,488 | 34,720 (0%) | 0% | 2.7 | 46,693 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 8,776 | 16,796 (0%) | 0% | 38.8 | 340,509 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 6,121 | 60,675 (0%) | 0% | 38.8 | 237,556 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 5,000 | 39,720 (0%) | 0% | 4.8 | 23,750 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 5,000 | 0 | - | - | Stock Options (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 31 Aug 2022 | 1,572 | 38,148 (0%) | 0% | 37.9 | 59,516 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 10 Mar 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 6,710 | 32,232 (0%) | 0% | 30.6 | 205,058 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 6,172 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 6,172 | 38,942 (0%) | 0% | 3.7 | 22,651 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 5,000 | 17,232 (0%) | 0% | 30.2 | 151,150 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 5,000 | 22,232 (0%) | 0% | 31.1 | 155,250 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 5,000 | 27,232 (0%) | 0% | 30.2 | 150,750 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 1,234 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 1,234 | 33,466 (0%) | 0% | 3.7 | 4,529 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 04 Mar 2022 | 696 | 32,770 (0%) | 0% | 31.4 | 21,868 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 13,374 | 40,491 (0%) | 0% | 3.9 | 51,490 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 13,374 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 12,345 | 29,141 (0%) | 0% | 3.8 | 46,417 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 12,345 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 3,155 | 35,144 (0%) | 0% | 18.8 | 59,346 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 2,912 | 32,232 (0%) | 0% | 18.8 | 54,775 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 2,192 | 38,299 (0%) | 0% | 18.9 | 41,451 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 28 May 2021 | 2,024 | 27,117 (0%) | 0% | 18.9 | 38,274 | Common Shares | |
| Xenon Pharmaceuticals Inc | Robin Sherrington | EVP, Strategy & Innovation | 12 Mar 2021 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) |